HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.

AbstractOBJECTIVES:
The purpose of this study was to examine the relationship between changes in pulmonary vascular resistance (PVR) and right ventricular ejection fraction (RVEF) and survival in patients with pulmonary arterial hypertension (PAH) under PAH-targeted therapies.
BACKGROUND:
Despite the fact that medical therapies reduce PVR, the prognosis of patients with PAH is still poor. The primary cause of death is right ventricular (RV) failure. One possible explanation for this apparent paradox is the fact that a reduction in PVR is not automatically followed by an improvement in RV function.
METHODS:
A cohort of 110 patients with incident PAH underwent baseline right heart catheterization, cardiac magnetic resonance imaging, and 6-min walk testing. These measurements were repeated in 76 patients after 12 months of therapy.
RESULTS:
Two patients underwent lung transplantation, 13 patients died during the first year, and 17 patients died in the subsequent follow-up of 47 months. Baseline RVEF (hazard ratio [HR]: 0.938; p = 0.001) and PVR (HR: 1.001; p = 0.031) were predictors of mortality. During the first 12 months, changes in PVR were moderately correlated with changes in RVEF (R = 0.330; p = 0.005). Changes in RVEF (HR: 0.929; p = 0.014) were associated with survival, but changes in PVR (HR: 1.000; p = 0.820) were not. In 68% of patients, PVR decreased after medical therapy. Twenty-five percent of those patients with decreased PVR showed a deterioration of RV function and had a poor prognosis.
CONCLUSIONS:
After PAH-targeted therapy, RV function can deteriorate despite a reduction in PVR. Loss of RV function is associated with a poor outcome, irrespective of any changes in PVR.
AuthorsMariëlle C van de Veerdonk, Taco Kind, J Tim Marcus, Gert-Jan Mauritz, Martijn W Heymans, Harm-Jan Bogaard, Anco Boonstra, Koen M J Marques, Nico Westerhof, Anton Vonk-Noordegraaf
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 58 Issue 24 Pg. 2511-9 (Dec 06 2011) ISSN: 1558-3597 [Electronic] United States
PMID22133851 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Topics
  • Cardiac Catheterization
  • Disease Progression
  • Exercise Test
  • Female
  • Humans
  • Hypertension, Pulmonary (complications, diagnosis, drug therapy, mortality)
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Stroke Volume
  • Survival Analysis
  • Vascular Resistance
  • Ventricular Dysfunction, Right (diagnosis, etiology, physiopathology)
  • Ventricular Function, Right

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: